Mary Dibiase Sells 22,258 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase sold 22,258 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $10,016.10. Following the transaction, the chief operating officer now directly owns 490,980 shares of the company’s stock, valued at approximately $220,941. This trade represents a 4.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Trading Down 2.0 %

XFOR stock opened at $0.48 on Wednesday. X4 Pharmaceuticals, Inc. has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a market capitalization of $82.17 million, a PE ratio of -5.35 and a beta of 0.14. The company’s 50-day simple moving average is $0.55 and its 200 day simple moving average is $0.61. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th. Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $30,000. SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter valued at $65,000. Rhumbline Advisers grew its holdings in shares of X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after purchasing an additional 126,296 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.